RE:RE:RE:RE:Cancer will cost the world $25 trillion over next 30 yearsBiopharma’s 25 largest companies have almost $1.5 Trillion in available “firepower”, EY estimates in its annual M&A Firepower report, a figure that has grown substantially since 2020. And Big Pharma faces a looming patent cliff.
In the process of taking the Trillion dollar cost of cancer and Big Pharma's firepower into consideration, the PD-(L)1 immune checkpoint inhibitor market is expected to reach US$135 Billion by 2030 with checkpoint inhibitors being only 10-20% efficient in treatment outcome.
In seeking to improve the effectiveness of immune checkpoint inhibitors, ONCY's pelareorep is intended to increase their efficacy by 2-3 times. ONCY has been demonstrating that pelareorep is capable of achieving enhanced anti-PD-(L)1 effectiveness by remodeling the TME and upregulating PD-L1 checkpoint ligand targets on the tumor cell surface, thus turning "cold" tumors into "hot" tumors in advance of the addition of checkpoint therapy. Achievement of this level would increase the market of checkpoint inhibitors from $US135 Billion to US$270-400 Billion.
Furthermore the global immunotherapy drugs market size is expected to reach around US$ 351.56 billion by 2030 without the enhanced use and increased market size that would occur of immune checkpoint inhibitors when combined with ONCY's pelareorep.
As further background in December 2022 Takeda spent US$4 Billion to acqure one Phase 2/Phase 3 ready psoriasis drug, ONCY' pelareorep is also a "Phase 3 ready" drug that is can potentially achieve "breakthrough" designation and an accelerated approval status in 2 cancer indications, that would result in immediate marketing approval followed-up with a post-marketing confirmatory trial for final FDA/EMA approval ... which Big Pharma would seek to acquire to bring to market.
This level of potential places ONCY in notable position as a M&A target for an acquisition by Big Pharma. And a target acquistion valuation for ONCY of US$10 Billion is in scope particularly since this proposed acquisition value falls within Big Pharma's acquisition "sweet spot" of US$5 to US$15 Billion, first cited by PwC.